Article Text

Download PDFPDF
Diabetes and coronary artery disease: time to stop taking the tablets
  2. R D RAKHIT,
  1. Department of Cardiology
  2. UMDS, Rayne Institute
  3. St Thomas’s Hospital, London SE1 7EH, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor,—We write in response to the editorial “Diabetes and coronary artery disease: time to stop taking the tablets”.1 The authors highlight previous studies where diabetic patients treated with sulphonylureas have an excess cardiovascular mortality during myocardial infarction compared with diabetic patients treated by other means. As Connaughton and Webber point out ischaemic preconditioning has refocused our attention on these trials.

The profound protective effects of ischaemic preconditioning are thought to be mediated by opening of a KATP channel, while the hypoglycaemic action of sulphonylureas is mediated by closure of these channels within the membrane of β cells in the islets of Langerhan. The authors suggest that it may be simply a case of “adding a potassium channel opener along with insulin during [myocardial infarction] MI” to improve outcome in diabetics presenting with infarction. However, recent findings suggest this is an oversimplification and probably incorrect.

One problem is that, there are at least two different KATP channels within cardiac myocytes. Evidence is emerging that it is the mitochondrial and not the cell membrane KATPchannels that initiates the cardioprotective effects of preconditioning. This conclusion is based on recent work from Marban’s group.2-4 These investigators show that …

View Full Text